Eversept Partners, LP Ac Immune Sa Transaction History

Eversept Partners, LP

$904 Million
Q1 2025

A detailed history of Eversept Partners, LP transactions in Ac Immune Sa stock. As of the latest transaction made, Eversept Partners, LP holds 100,752 shares of ACIU stock, worth $169,263. This represents 0.02% of its overall portfolio holdings.

Number of Shares

100,752

Holding current value

$169,263

% of portfolio

0.02%

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$1.87 - $2.98 $188,406 - $300,240	100,752 New	100,752 $188,000
Q2 2024 Aug 14, 2024	SELL	$2.29 - $4.87 $57,882 - $123,094	-25,276 Reduced 20.29%	99,313 $396,000
Q1 2022 May 16, 2022	SELL	$3.5 - $5.16 $100,768 - $148,561	-28,791 Reduced 18.77%	124,589 $498,000
Q4 2021 Nov 08, 2023	SELL	$4.83 - $7.56 $330,222 - $516,869	-68,369 Reduced 30.83%	153,380 $759,000
Q4 2021 Feb 14, 2022	SELL	$4.83 - $7.56 $330,222 - $516,869	-68,369 Reduced 30.83%	153,380 $759,000
Q3 2021 Nov 08, 2023	BUY	$6.2 - $8.34 $602,392 - $810,314	97,160 Added 77.98%	221,749 $1.49 Million
Q3 2021 Nov 15, 2021	BUY	$6.2 - $8.34 $1.37 Million - $1.85 Million	221,749 New	221,749 $1.49 Million

Others Institutions Holding ACIU

# of Institutions

Shares Held

27.4M

Call Options Held

4.8K

Put Options Held

22.2K

Bvf Inc San Francisco, CA

19.8M
Shares

$33.3 Million
1.63% of portfolio
Black Rock Inc. New York, NY

2.61M
Shares

$4.38 Million
0.0% of portfolio
Wells Fargo & Company San Francisco, CA

998K
Shares

$1.68 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

803K
Shares

$1.35 Million
0.0% of portfolio
Platinum Investment Management LTD Sydney Australia 2000, C3

739K
Shares

$1.24 Million
0.09% of portfolio

View Full List

About AC Immune SA

Ticker ACIU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,413,504
Market Cap $140M
Description
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectiv...

More about ACIU

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Eversept Partners, LP, based on Form 13F filings with the SEC.

News

Stay updated on Eversept Partners, LP with notifications on news.

Account